Investigational Drug Treatments for Triple-Negative Breast Cancer.
PARP inhibitors
PI3kb/mTOR inhibitors
histone deacetylase inhibitors
immunotherapy
novel therapeutic strategies
targeted therapies
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
10 Jul 2021
10 Jul 2021
Historique:
received:
23
05
2021
revised:
25
06
2021
accepted:
08
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10-20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which constitutes the most often recommended treatment. New beneficial targeted therapies are important to be investigated in order to achieve enhanced outcomes in patients with TNBC. This review will focus on recent therapeutic innovations for TNBC, focusing on various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase inhibitors, histone deacetylase inhibitors (HDACIs), and immune checkpoint inhibitors.
Identifiants
pubmed: 34357119
pii: jpm11070652
doi: 10.3390/jpm11070652
pmc: PMC8303312
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Oncologist. 2017 Jan;22(1):25-32
pubmed: 27789775
Science. 1996 Mar 15;271(5255):1513-8
pubmed: 8599106
Oncotarget. 2018 Apr 10;9(27):18985-18996
pubmed: 29721177
Oncotarget. 2020 Mar 17;11(11):969-981
pubmed: 32215185
Biochem Pharmacol. 2012 Jul 15;84(2):137-46
pubmed: 22469522
Nat Rev Cancer. 2012 Jun 22;12(7):465-77
pubmed: 22722403
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
BMC Cancer. 2018 Nov 6;18(1):1074
pubmed: 30400780
Asian Pac J Cancer Prev. 2016;17(S3):43-6
pubmed: 27165206
J Cell Sci. 2006 Sep 1;119(Pt 17):3664-75
pubmed: 16912073
Adv Cancer Res. 2012;116:199-237
pubmed: 23088872
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Neoplasma. 2018 Nov 15;65(6):898-906
pubmed: 30334455
J Natl Cancer Inst. 2007 Dec 5;99(23):1811-4
pubmed: 18042939
J Cell Mol Med. 2014 Jun;18(6):947-61
pubmed: 24712303
Clin Cancer Res. 2012 Mar 15;18(6):1655-62
pubmed: 22291137
Exp Hematol Oncol. 2015 Mar 01;4:7
pubmed: 25745591
Invest New Drugs. 2016 Jun;34(3):355-63
pubmed: 26996385
J Biol Chem. 2005 Jul 8;280(27):25892-900
pubmed: 15886206
Ann Oncol. 2004 Jun;15(6):891-5
pubmed: 15151945
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Mol Cell. 2015 Dec 3;60(5):755-768
pubmed: 26626480
Hematol Oncol Clin North Am. 2012 Jun;26(3):649-70, ix
pubmed: 22520984
Anticancer Res. 2017 Jan;37(1):35-46
pubmed: 28011471
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1495-506
pubmed: 26359465
Nat Rev Mol Cell Biol. 2003 Nov;4(11):842-54
pubmed: 14625535
Clin Cancer Res. 2017 Nov 1;23(21):6468-6477
pubmed: 29093017
Breast Cancer Res Treat. 2018 Aug;171(1):43-52
pubmed: 29752686
Anticancer Res. 2019 Oct;39(10):5285-5296
pubmed: 31570423
Clin Cancer Res. 2008 Mar 15;14(6):1639-48
pubmed: 18347165
Mol Cancer Ther. 2014 Sep;13(9):2170-83
pubmed: 24980948
J Clin Oncol. 2005 Feb 10;23(5):1011-27
pubmed: 15585754
Biomaterials. 2016 Sep;101:20-31
pubmed: 27267625
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
Mol Cancer Ther. 2014 Dec;13(12):3175-84
pubmed: 25253784
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Breast Cancer Res. 2017 Aug 15;19(1):93
pubmed: 28810913
Cancer. 2017 Jan 1;123(2):219-227
pubmed: 27683209
Invest New Drugs. 2015 Aug;33(4):890-4
pubmed: 25947565
In Vivo. 2020 Jul-Aug;34(4):1715-1727
pubmed: 32606140
Ann Oncol. 2021 May;32(5):652-660
pubmed: 33539944
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Anticancer Drugs. 2018 Sep;29(8):774-785
pubmed: 29878901
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
pubmed: 11252954
Oncogene. 2006 Sep 25;25(43):5898-905
pubmed: 16998504
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
J Cell Biol. 2006 Jun 19;173(6):833-7
pubmed: 16769825
Cell Cycle. 2016 Sep;15(17):2265-74
pubmed: 27027731
Ann Oncol. 2021 Feb;32(2):240-249
pubmed: 33242536
Nat Rev Neurol. 2010 Feb;6(2):99-107
pubmed: 20139999
Invest New Drugs. 2020 Oct;38(5):1400-1410
pubmed: 31953695
Breast Cancer Res. 2015 Mar 07;17:33
pubmed: 25888415
Nat Med. 1997 Feb;3(2):222-5
pubmed: 9018243
Mol Cancer Ther. 2011 Aug;10(8):1460-9
pubmed: 21690228
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Mol Med. 2005 Jan-Dec;11(1-12):1-15
pubmed: 16557334
J BUON. 2018 Jul-Aug;23(4):846-861
pubmed: 30358185
Cancer Res. 2017 Jan 15;77(2):566-578
pubmed: 27872098
Signal Transduct Target Ther. 2016 Jul 01;1:16010
pubmed: 29263896
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Crit Rev Oncol Hematol. 2017 Nov;119:59-65
pubmed: 29065986
Breast Cancer Res Treat. 2015 Nov;154(2):351-7
pubmed: 26536871
Exp Neurol. 2010 Jun;223(2):252-66
pubmed: 19716367
J Biol Chem. 1999 Mar 12;274(11):7334-40
pubmed: 10066797
Cancer. 1997 Aug 15;80(4):753-63
pubmed: 9264360
Iran Biomed J. ;22(2):76-7
pubmed: 29101913
Oncologist. 2018 Nov;23(11):1300-1309
pubmed: 30139837
Future Oncol. 2019 Jun;15(17):1951-1961
pubmed: 30977385
Cancer. 2002 Mar 1;94(5):1593-611
pubmed: 11920518
Int Rev Cell Mol Biol. 2011;287:233-86
pubmed: 21414590
N Engl J Med. 2005 Jul 14;353(2):172-87
pubmed: 16014887
Nature. 1992 Mar 26;356(6367):356-8
pubmed: 1549180
Science. 1989 Dec 8;246(4935):1306-9
pubmed: 2479986
Mol Cancer Ther. 2006 Jul;5(7):1693-701
pubmed: 16891455
Bioorg Chem. 2021 Jun;111:104872
pubmed: 33838560
Int J Cancer. 2006 Jul 15;119(2):275-82
pubmed: 16477625
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):299-313
pubmed: 28870998
Cancer Res. 2000 Aug 1;60(15):4000-4
pubmed: 10945597
Invest New Drugs. 2018 Dec;36(6):1060-1071
pubmed: 29980894
Sci Rep. 2019 Sep 16;9(1):13305
pubmed: 31527644
Mol Cell. 2015 Dec 3;60(5):742-754
pubmed: 26626479
Breast Cancer Res. 2019 Nov 8;21(1):119
pubmed: 31703728
Cancer Chemother Pharmacol. 2020 Apr;85(4):673-683
pubmed: 32062691
Clin Cancer Res. 2001 Jul;7(7):1850-5
pubmed: 11448895
Lancet Oncol. 2021 Apr;22(4):499-511
pubmed: 33676601
J Cell Sci. 1999 Nov;112 ( Pt 21):3591-601
pubmed: 10523496
Ann Oncol. 2004 Mar;15(3):440-9
pubmed: 14998846
PLoS One. 2015 Nov 05;10(11):e0141763
pubmed: 26540293
Cancer Chemother Pharmacol. 2020 Apr;85(4):741-751
pubmed: 32055930
J Med Chem. 2017 Jun 8;60(11):4533-4558
pubmed: 28195723
N Engl J Med. 2002 Nov 14;347(20):1566-75
pubmed: 12432043
Cancer Res. 2016 Aug 1;76(15):4493-503
pubmed: 27325647
Endocr Relat Cancer. 2001 Mar;8(1):3-9
pubmed: 11350723
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Expert Opin Investig Drugs. 2017 Nov;26(11):1199-1206
pubmed: 28952409
Genomics. 1998 Nov 1;53(3):406-9
pubmed: 9799611
Expert Opin Ther Targets. 2008 Jan;12(1):69-80
pubmed: 18076371
Trends Biochem Sci. 2016 Jan;41(1):46-61
pubmed: 26705895
Clin Cancer Res. 2017 Aug 1;23(15):4035-4045
pubmed: 28270498
Cancer. 2002 Jun 1;94(11):2874-81
pubmed: 12115375
Oncogene. 2002 Jan 17;21(3):427-36
pubmed: 11821955
EMBO J. 1998 Jun 1;17(11):3052-65
pubmed: 9606188
Nat Rev Drug Discov. 2014 Feb;13(2):140-56
pubmed: 24481312
Mol Biol Cell. 2010 Jul 15;21(14):2371-83
pubmed: 20484572
Recent Pat Anticancer Drug Discov. 2017 Nov 20;12(4):340-364
pubmed: 28786345
Front Oncol. 2020 Jan 23;9:1534
pubmed: 32039017
Mol Cell. 2010 Jul 9;39(1):8-24
pubmed: 20603072
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Front Oncol. 2021 May 05;11:668464
pubmed: 34026646
Cancer Lett. 2012 Jun 1;319(1):1-7
pubmed: 22261336
Am J Pathol. 2013 Oct;183(4):1113-1124
pubmed: 23993780
Cancer Cell. 2015 Aug 10;28(2):155-69
pubmed: 26267533
JAMA Oncol. 2017 Apr 01;3(4):509-515
pubmed: 27893038
Invest New Drugs. 2015 Oct;33(5):1108-14
pubmed: 26123926
Clin Breast Cancer. 2018 Feb;18(1):88-94
pubmed: 29153775
Int J Oncol. 2019 Jul;55(1):116-130
pubmed: 31059004